|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.
|
|
 |
|
For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.
|
|
 |
|
Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.
|
|
|
|
|
|
|
|
|
Shaukat Ali, PhD, and Jim Huang, PhD, explain how lyophilization or freeze-drying technology is one of the ideal methods that leads to immobilization of drug and other components that remain in solid or powder state for extended periods without concerns of degradation, and how it has also been applied to improve drug solubility by means of amorphous solid dispersions.
|
|
|
Anette Müllertz, PhD, Grace Furman, PhD, and Lisa Caralli say developers should first understand the developability challenges for their molecule, then a toolkit of enabling technologies can be identified to overcome those factors and individually leveraged to create fit for purpose formulations for use in preclinical and clinical studies.
|
|
|
Timothy Pas, PhD, and Vincent Levet, PhD, believe different solubility-enhancing technologies can be used by developers, and with different advantages and drawbacks, linked to payload, manufacturability, tolerability, and physical and chemical stability, effectively navigating solubility-enhancing solutions is multifaceted.
|
|
|
Suzanne Saffie-Siebert, PhD, Michael Welsh, PhD, Nissim Torabi-Pour, PhD, and Flavia M. Sutera, PhD, review current shortcomings, as well as some accompanying manufacturing challenges, and will show how they can be addressed by SiSaf’s silicon-stabilized hybrid LNPs.
|
|
|
|
|
|
|
|
|

As a global leader in pharmaceutical and medical device testing, Element Materials Technology delivers comprehensive testing solutions that ensure product safety, quality, and regulatory compliance at every stage of development. From initial R&D through commercialization, our 150+ pharmaceutical experts worldwide bring over four decades of experience to your critical projects. Our expertise spans a comprehensive range of specialized capabilities including, but not limited to, biologics testing, Chemical, Manufacturing, and Controls (CMC), biocompatibility assessment, PFAS testing, extractables and leachables studies, and comprehensive antimicrobial and disinfectant analysis. Click here for more.
|
|
|
|
|
|
 |
|
Intensified upstream bioprocesses are being developed to increase productivity while reducing footprint, costs, and timelines for manufacturing. The higher cell densities generated by….
|
|
 |
|
Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on
|
|
|
|
|
|
|
|
 |
|
Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …
|
|
 |
|
By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks …
|
|
 |
|
A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …
|
|
|
|
|
Upcoming eNewsletter Features:
February 5 – Analytical Testing
February 12 – Injection Devices
|
|
|
|
|
|
|
|